La empresa Mweive Bio lleva 9 años en pérdidas y planea recaudar fondos en Hong Kong; en 2022, planea cotizar en A-shares y recaudar 3.5 mil millones de yuanes

China Economic Net, Beijing, March 25—Wei Bio(688062.SH) released its 2025 annual report late yesterday evening. During the reporting period, the company achieved operating revenue of 6.63 billion yuan, a year-on-year increase of 231.62%; it achieved a net profit attributable to shareholders of -969 million yuan, compared with -1.044 billion yuan in the prior year; it achieved a net profit attributable to shareholders after deducting non-recurring gains and losses of -999 million yuan, compared with -1.070 billion yuan in the prior year; net cash flow from operating activities was -290 million yuan, compared with -956 million yuan in the prior year.

Wei Bio has been loss-making for 9 consecutive years.

From 2017 to 2023, Wei Bio’s net profit attributable to shareholders was -103 million yuan, -225 million yuan, -928 million yuan, -643 million yuan, -770 million yuan, -955 million yuan, and -1.053 billion yuan, respectively.

Wei Bio was listed on the Shanghai Stock Exchange’s Science and Technology Innovation Board on January 18, 2022. The number of issued shares was 99.90 million shares, the issue price was 34.80 yuan per share, the sponsor (sole lead underwriter) was Haitong Securities (current name: Guotai Haitong), and the sponsor representatives were Wang Yongjie and Chen Xinjun.

The total proceeds from Wei Bio’s initial public offering of shares were 3.477 billion yuan; after deducting issuance expenses, the net proceeds were 3.303 billion yuan. The final net proceeds were 323 million yuan more than the original plan. The prospectus disclosed by Wei Bio on January 10, 2022 shows that the company planned to raise 2.98 billion yuan for the annual production of 1000kg antibody industrialization construction project, antibody drug R&D project, and replenishment of working capital, respectively.

Total issuance expenses for Wei Bio’s initial public offering of shares were 185 million yuan, including underwriting and sponsorship fees of 155 million yuan.

In addition, on the evening of August 31, 2025, Wei Bio disclosed an announcement regarding re-submission of its application for H-share issuance and listing to the Hong Kong Stock Exchange, and the publication of application materials.

According to an announcement disclosed by Wei Bio on November 21, 2025 regarding the filing with the China Securities Regulatory Commission for the issuance of overseas listed foreign shares (H shares), the company has recently received a notice issued by the China Securities Regulatory Commission, titled “Notice of Filing for Overseas Issuance and Listing of Wei (Shanghai) Bio-Technology Co., Ltd.” (Guo He Han〔2025〕2062) (hereinafter referred to as the “Filing Notice”). The main contents of the Filing Notice are as follows: “1. The company intends to issue no more than 62,664,600 overseas listed ordinary shares and list them on the Hong Kong Stock Exchange. 2. From the date of issuance of this Filing Notice until the conclusion of this overseas issuance and listing, if the company experiences any major matter, it shall, pursuant to the relevant provisions on overseas issuance and listing by domestic enterprises, report through the filing management information system to the China Securities Regulatory Commission. 3. Within 15 business days after completing the overseas issuance and listing, the company shall report the details of its issuance and listing through the filing management information system to the China Securities Regulatory Commission. During the overseas issuance and listing process, the company shall strictly comply with laws, regulations, and rules applicable both domestically and overseas. 4. If the company has not completed the overseas issuance and listing within 12 months from the date of issuance of this Filing Notice, and intends to continue to advance the matter, it shall update the filing materials.”

(Editor: Ma Xin)

Massive information and precise analysis—available on Sina Finance App